chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Slight body acheyness; Arm pain at injection site in left arm; Booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 26 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 15Dec2021 (Lot number: FH8027) at the age of 26 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EL3247), administration date: 05Feb2021, when the patient was 25 years old, for Covid-19 Immunization; Bnt162b2 (Dose Number: 2, Batch/Lot No: EL3247), administration date: 25Feb2021, when the patient was 25 years old, for Covid-19 Immunization. The following information was reported: IMMUNISATION (non-serious) with onset 15Dec2021, outcome "unknown", described as "Booster"; PAIN (non-serious) with onset 15Dec2021 17:00, outcome "recovering", described as "Slight body acheyness"; VACCINATION SITE PAIN (non-serious) with onset 15Dec2021 17:00, outcome "recovering", described as "Arm pain at injection site in left arm". Therapeutic measures were not taken as a result of pain, vaccination site pain. No follow-up attempts are possible. No further information is expected.  Additional information: This is not serious case. It did not meet any of the seriousness criteria. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient was not diagnosed with COVID-19, prior to vaccination. Patient has not been tested positive since the vaccination.  Follow-up attempts are completed. No further information is expected.
Pt recv vax on 1/19/98; subsequently pt exp rx at injection site of redness, swelling &warmth. On 1/21/98 pt saw M.D.; tx=warm compresses &Biaxin.
Info has been received from a Dr concerning a 1 yr old pt who was vaccinated with measles virus vaccine live and mumps virus vaccine live and rubella virus vaccine live (second generation) The pt also received varicella virus vaccine (MSD). Subsequently the pt developed localized redness at both injection sites. The pt pulled away during vaccination with varicella virus vaccine and received only half the dose. The pt was treated with Benadryl and the pt recovered.
Syncope episodes.  10/25/2007 MR received for DOS 10/08-12/2007 for D/C DX: Syncopal episodes thought to be likely 2' to HPV vaccine administration. Orthostasis (contributing factor to syncopal episodes). Acute on chronic headache.  Chronic low back pain. Chronic pain syndrome.  Depression.  Nodule infiltrate on lingula per CT scan.  Pt presented to ER with c/o multiple syncopal episodes.  Pt developed nausea and H/A ~ 15 minutes after HPV vax.  Within 30" she had 1st syncopal episode where pt fell and hit her head. MD recommended increased po fluids and Benadryl, however pt had another episode that pm. En route to ER pt lost consciouness for few seconds. Pt was discharged from ER (10/3/07) but had 5 more syncopal episodes over the next several days. Also c/o generalized weakness, decreased appetite, and tiredness. Pt had cardiac and neuro consults.  Pt was found to be orthostatic and several medications were d/cd as they may havbe been contributing. Last syncopal episode was 10/9/07 Per 60 day follow up: Patient with residual dizziness & fainting spells, currently being evaluated by neurology and cardiology.
Patient passed out twice. Once a day after the vaccination, and another time 2 days post vaccination
no adverse effects reported; patient was vaccinated with improperly stored MMR II; This spontaneous report has been received from a medical assistant, concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided.  On 30-MAY-2019, the patient was vaccinated with improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (albumin status rHA) one dose, lot # R024906 with expiration date 30-AUG-2020 (frequency, route and anatomical location were not provided) which was reconstituted with sterile diluent (dose, frequency, route, lot number and expiration date were not provided) for prophylaxis. No adverse effects reported.  The temperature and time frame were unknown by reporter. There was previously temperature excursions and digital data logger was involved.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1906USA011469: US-009507513-1907USA010301: US-009507513-1907USA010302: US-009507513-1907USA010303: US-009507513-1907USA010304: US-009507513-1907USA010305: US-009507513-1907USA010306: US-009507513-1907USA010307: US-009507513-1907USA010308: US-009507513-1907USA010309: US-009507513-1907USA010310: US-009507513-1907USA010311: US-009507513-1907USA010312: US-009507513-1907USA010313: US-009507513-1907USA010314: US-009507513-1907USA010315: US-009507513-1907USA010316: US-009507513-1907USA010317: US-009507513-1907USA010318: US-009507513-1907USA010319: US-009507513-1907USA010320: US-009507513-1907USA010321: US-009507513-1907USA010322: US-009507513-1907USA010323: US-009507513-1907USA010324: US-009507513-1907USA010325: US-009507513-1907USA010326: US-009507513-1907USA010327: US-009507513-1907USA010328: US-009507513-1907USA010329: US-009507513-1907USA010330: US-009507513-1907USA010331: US-009507513-1907USA010332: US-009507513-1907USA010333: US-009507513-1907USA010334: US-009507513-1907USA010335: US-009507513-1907USA010336: US-009507513-1907USA010337: US-009507513-1907USA010338: US-009507513-1907USA010339: US-009507513-1907USA010340: US-009507513-1907USA010341: US-009507513-1907USA010342: US-009507513-1907USA010343: US-009507513-1907USA010344: US-009507513-1907USA010345: US-009507513-1907USA010346: US-009507513-1907USA010347: US-009507513-1907USA010348: US-009507513-1907USA010349: US-009507513-1907USA010350: US-009507513-1907USA010351: US-009507513-1907USA010352: US-009507513-1907USA010353: US-009507513-1907USA010354: US-009507513-1907USA010355: US-009507513-1907USA010356: US-009507513-1907USA010357: US-009507513-1907USA010358: US-009507513-1907USA010359: US-009507513-1907USA010360: US-009507513-1907USA010361: US-009507513-1907USA010362: US-009507513-1907USA010363: US-009507513-1907USA010364: US-009507513-1907USA010365: US-009507513-1907USA010366: US-009507513-1907USA010367: US-009507513-1907USA010368: US-009507513-1907USA010369: US-009507513-1907USA010371: US-009507513-1907USA010372: US-009507513-1907USA010373:
J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/20/2023 DM 2 W ULCER OF LEFT FOOT
Patient was under 18 at the time of vaccination. Notified the facility where the vaccine was given (the patents employer) and followed up with the patient. No adverse events or serious side effects reported.
The night of shot, it got hot, swollen, hard. 1 hr, night of administration.
Systemic: Dizziness / Lightheadness-Medium, Systemic: Flushed / Sweating-Medium, Systemic: Nausea-Medium, Systemic: Vomiting-Medium, Additional Details: Approximately 10 seconds after vaccine administration the patient felt dizzy and hot and began vomiting. The patient told the immunizer that she was scared of needles but never threw up after receiving a vaccination. The patient was observed for an additional 30 minutes given water and vitamin water and then her father agreed the patient was okay to leave.
fever w/in 36hrs of vax & faint pink-red rash on proximal thighs & forearms;
Bell's Palsy; This is a spontaneous report received from a contactable reporter (Physician) from medical information team and a sales representative.  A 51 year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), administration date 2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (First Dose), for Covid-19 Immunization. The following information was reported: BELL'S PALSY (medically significant) with onset 2021, outcome "recovering", described as "Bell's Palsy". The event "bell's palsy" was evaluated at the emergency room visit. The patient underwent the following laboratory tests and procedures: spike protein AB: more than 250. Therapeutic measures were taken as a result of bell's palsy, included steroids. Clinical course was as follows; The reporter was asking for the recommendations from Pfizer for Covid-19 Booster Vaccination for a patient who had Bell's Palsy after 2nd Pfizer-BioNTech Covid-19 vaccination. The patient had symptoms of left eye tearing then facial weakness 12 days after second covid vaccine. Diagnosed (Dx) to have "L Bells palsy" 05Jun2021 at PRIVACY ER. Treated with 2 courses of steroids and had good outcome with still some residual abnormal blinking slower on the left. Event took place after use of product.  The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: A possible contribution role of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) to the onset of Bell's Palsy cannot be excluded, considering the temporal relationship.  The case will be reassessed should additional information become available.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics committees and Investigators, as appropriate.
This spontaneous report as received from a other refers to a patient of unknown age. On an unknown date the patient was vaccinated with PNEUMOVAX 23 for prophylaxis. On an unknown date the patient experienced product use issue and no adverse event. The outcome of product use issue and no adverse event is unknown. The reporter considered product use issue and no adverse event to be not related to PNEUMOVAX 23. Additional information has been requested.
For 3-4 days after the vaccine, child had redness and swelling at the site. Also for two days after the vaccine, she had a fever of 100-102 and both of her ears had blisters.
Vaccine (HepB) admin around 10:46am, cried, had 2 oz bottle prior to vaccine. Fed baby at home, held him in transverse/lat position, around 4pm baby unresponsive, limp, shallow breathing, last about 20 min, police arrived, then EMS, temp 100.5 rectal in ED, admitted for full sepsis w/u.
Initial health authority report received on 05 Jan 2010: This patient was vaccinated with H1N1 influenza virus vaccine (manufacturer unknown) on 10 Dec 2009. After vaccination, the patient suffered from pneumonia, type-1 diabetes mellitus and diabetic ketoacidosis since 11 Dec 2009. Outcome of the events was not reported. Follow up received on 05 Mar 2010: As the case as received form webiste of local centers for disease control, no further information was available. Follow-up report received from local health authority on 30 Mar 2010: The patient did not receive Novartis vaccine FOCETRIA. Therefore, this case became invalid and would be deactivated.
Left side has swollen lymph node in torso under armpit near breast. Very tender. Larger than a golf ball, smaller than a baseball. Started the day after the vaccine. Pharmacist advised patient to have it evaluated by a medical doctor.
Drooping Left side of face. Was advised to go to hospital for possible stroke. He was completely  tested and checked for possible stroke. Was given DX of Bell?s Palsy along with scripts for steroids and antiviral.
Immediate dizziness lasting 10 minutes or so followed by slow swelling of injection site which has spread over the last 3 days.  Now itchy.
syncope sp vaccine diaphoretic pale, VSS with EMT, monitored for 30 min, refused hospital, wife drove home.  hx of syncope sp vaccines blood drawl
This spontaneous report as received from an 82 years old female patient with arthritis, codeine allergy and sulfate allergy refers to herself. The patient's medical history included shingles and gall bladder removed. The patient was vaccinated with ZOSTAVAX on an unspecified date after she had shingles. No other co-suspects were reported. Concomitant medications included aspirin and MOTRIN. The patient mentioned that she had experienced post herpetic neuralgia for the past 4 years, in 2008. She had tried morphine and oxycodone no relieve the pain, but they did not work. The patient mentioned that wearing a bra was painful. The patient experienced shooting pains. All AE responses are for ZOSTAVAX. The patient had visited the doctor for medical attention. The outcome was reported as not recovered/not resolved. Additional information has been requested.
Extreme shoulder pain(10/10), full arm/hand numbness/immovability, shaking, radiating pain to chest and back, metallic taste in mouth. stayed 9 hours in the emergency room.
Patient received dose of MENACTRA as required for school. As Patient was leaving the Pharmacy he felt faint. Patient skin was pale, he did not lose consciousness, was awake. Mother and I assisted the patient. It took about 1min-1.5 min he was completed recovered. Pat. had a drink of juice and left the store.
Myalgia, Arthralgia, Pain & discomfort at injection site; symptoms lasting ~5 days Narrative:
Information has been received from a physician, for GARDASIL, a Pregnancy Registry product, concerning a 20 year old female patient who on 29-JAN-2009 was vaccinated with the first dose of GARDASIL (No lot number provided). Subsequently the patient became pregnant after receiving GARDASIL. The patient's date of last menstrual period was approximately on 03-AUG-2009 and estimated delivery date is 20-MAY-2010. Series of GARDASIL was discontinued. Unspecified medical attention had been sought. Follow up information has been received from an obstetrical (OB) coordinator who reported that the patient's last GARDASIL was given to this patient on 29-JAN-2009 and her LMP prior to this pregnancy was in July 2009 (previously reported as "approximately on 03-AUG-2009"). This patient delivered twins in May 2010 via a scheduled cesarean section, due to Baby A being in breech position. The OB coordinator didn't know the exact gestational age, but stated the twins were at term, "so at least 38 weeks." She said the mother was doing well, but she could not tell me what the health of the babies was; she did not have any information related to the status of the twins. No further information is available.
Patient came in with father feeling very nervous and scared and clearly did not want the shot. Shot was given and about 10 minutes later she felt like she was going to faint but she did not. She sat done for 10 minutes with father and then left without any other issues. I think the patient was just very scared and nervous.
1wk post vax pt had high temp increasing to 103-taken to ER;febrile sz lasting several min;limp-nonresponsive for sometime;fever a few days p/vax;now evaluating for autism, speech & language impaired, socially retarded;
Facial tingling on the left side jaw area; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the right arm on 23Mar2021 at 17:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included Human Immunodeficiency Virus (HIV) and hyperhidrosis. The patient had no known allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included oxybutynin (MANUFACTURER UNKNOWN), emtricitabine, rilpivirine hydrochloride, tenofovir alafenamide fumarate (ODEFSEY) and doxycycline (MANUFACTURER UNKNOWN), all taken for an unspecified indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6205) via an unspecified route of administration in the right arm on 02Mar2021 at 17:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. On 23Mar2021 at 17:30, 20 or 30 minutes after receiving the second dose of Pfizer COVID-19 vaccine, the patient experienced facial tingling on the left side jaw area. Facial tingling reoccurred the following day, 24Mar2021 at 20:30 and was present while filling out this report. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event facial tingling on the left side jaw area was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
She said it started later in the afternoon and she had a headache, her eyes got very red and was not very lucid. Her throat felt obstructed and she went to the hospital where they treated her for a major allergic reaction she said.
Patients stated that arm was red, warm to touch, swollen, and painful on Saturday 02/06/21.  Patient was seen at the ER on 02/09/2021 and prescribed antibiotic for cellulitis.  Patient states arm is feeling better today, 02/10/2021 but not completely resolved.
Left arm severe pain(could not lift left arm), left shoulder joint pain, Severe chills, body aches, severe headache, fever, sweats and fatigue.
fever 102, chills, vomit, dizzy, passing out, severe headache, heart racing, lasted 2 days, finally after second day could hold down water and tiny bit of toast fever of 99-100 lasted 2 more days, still hard to hold down anything. On day 6 still weak, shaky feeling bad. This sucks!
Pt stated she has POTS syndrome and was feeling dizzy. Pt given 2 bottles of gatorade and monitored for additional 15 minutes. Pt tolerated fluids well and stated she felt better and was ready to leave. Walked pt to front door where fiance was meeting her.  Pt denied any additional symptoms and stated if her symptom worsened she would go to the emergency room.
2 minutes after MMRV was administered, a hive was noted on the patient's right thigh just below injection site. The patient was given 5 mL of benadryl and monitored by APRN. Pt's parent was advised on after care and signs and symptoms warranting ED eval. by APRN and mother verbalized understanding before leaving clinic.
Experiencing a "burning, tingling" sensation in her upper body, chest, back, face,  head, and arms/she felt this sensation in her feet and leg as well; experiencing a "burning, tingling" sensation in her upper body, chest, back, face,  head, and arms/she felt this sensation in her feet and leg as well; She is worried that she may have some type of nerve damage; This is a spontaneous report from a non-contactable consumer (patient). A female patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 10Apr2021 (Lot number was not reported) as single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The following Wednesday night on 14Apr2021, the patient started experiencing a "burning, tingling" sensation in her upper body, chest, back, face, head, and arms. She reported that yesterday she felt this sensation in her feet and leg as well, and reported that today she still had the "tingling" going on in her body. She reported that when she drink water, it seemed to help. Caller would like to know if this was a normal side effect following the vaccine. She was worried that she may have some type of nerve damage. The outcome of events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Information has been received from a health professional concerning a 24 year old female who on 09-MAR-2007 was vaccinated, IM 0.5 ml first dose, with Gardasil (lot# 657006/0188U).  On 09-MAR-2007 the patient experienced nausea and diarrhea.  On 12-MAR-2007 the patient experienced a rash on her chest and chest pain.  Subsequently, the patient recovered from nausea, diarrhea, rash and chest pain.  The patient sought unspecified medical attention.  Additional information has been requested.
Patient presented with Baker's Cyst on Sept 01, 2021 - 2.5 months after 2nd "vaccination."  She tested posted on December 15, 2021 for COVID and two weeks later presented with Baker's cyst eruption / Reactive Arthritis.
started to get sore the same night of the shot.  When I woke up in the morning I was getting stomach cramps (lasted for several hours), nausea, temperature, extremely tired, terrible body aches in arm pits, knees, groin area, neck, back, everywhere,  Temperature of 100.4 chills.  This lasted for 24 hours.  Started to feel a little better, but then started to get pain in my neck, shoulder, and arm.  The same side as the injection site.  The neck on my right side was swollen and body ached.  Saturday afternoon, 3rd day after the shot I am still experiencing body aches and my neck is sore on both sides.
No additional AE; products experienced an excursion/have been administered to patients; This spontaneous report was received from a nurse referring to an 4-year-old patient of unknown gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On 16-SEP-2021, the patient was vaccinated with varicella virus vaccine live (Oka/Merck) (VARIVAX) 1 dose (Lot# U015682 has been verified to be a valid lot number for varicella virus vaccine live (Oka/Merck) (VARIVAX), expiration date reported as 18-MAY-2023) (strength, dose, route, frequency, were not provided) for prophylaxis.  The nurse reported that the vaccine experienced an excursion of 4 Celsius degrees (C) from -10 C to 8 C for 20 minutes on 07-SEP-2021 during the transport; and of 4C from -10 C to 8 C for 20 minutes on 09-SEP-2021, again during transport. Previous temperature excursion included from -10°C to 8°C (4C) for 7 hours and 30 minutes. And no adverse events were reported.  This is one of 26 reports received from the same source.; Sender's Comments:  US-009507513-2109USA005628:
Respiratory disorder. A territory representative reported that a male patient, with a history of asthma, received an injection of Prevnar. Subsequently he developed a fever and the need for extensive breathing treatments. No further information was available at the date of this report.
Received vaccine Nov 2. Early next morning Nov 3 I noticed my pulse was racing. Measured at 95 beats per minute. Around 7 am Nov 4 measured pulse again at 108.  Contacted urgent care and made appointment that morning. Doctor did EKG and took blood. He thought the tachycardia was due to my being dehydrated and ordered fluid intravenously. Heartbeat did slow down a bit after this, but he still described it as "fast." By the next day, Nov 4, heartbeat was lower, in the 90's. By Nov 5, heartbeat was normal, around 70. Was my problem truly dehydration (I've never had this problem before) or was it due to the effect of the vaccine?